Acamprosate-d₃ calcium

Name: Acamprosate-d 3 calcium
Brand: MedChemExpress
SKU: HY-17030S
Rating: 4.5 (1 reviews)

Cat. No.: HY-17030S Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Acamprosate-d₃ (calcium) is the deuterium labeled Acamprosate calcium. Acamprosate calcium is a GABA receptor agonist and modulator of glutamatergic systems[1][2].

For research use only. We do not sell to patients.

Acamprosate-d<sub>3</sub> calcium Chemical Structure

Acamprosate-d₃ calcium Chemical Structure

CAS No. : 1225580-94-8

Size	Price	Stock	Quantity
1 mg	USD 210	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 580	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 980	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Acamprosate-d₃ calcium:

Acamprosate calcium In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Acamprosate-d₃ (calcium) is the deuterium labeled Acamprosate calcium. Acamprosate calcium is a GABA receptor agonist and modulator of glutamatergic systems[1][2].

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

203.26

Formula

C₅H₇D₃CaNO₄S⁺

CAS No.

1225580-94-8

Appearance

Solid

Color

White to off-white

SMILES

O=S(CCCNC(C([2H])([2H])[2H])=O)([O-])=O.[Ca+2].[0.5]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H2O : 100 mg/mL (491.98 mM; Need ultrasonic)

DMSO : ≥ 1 mg/mL (4.92 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.9198 mL	24.5990 mL	49.1981 mL
5 mM	0.9840 mL	4.9198 mL	9.8396 mL
10 mM	0.4920 mL	2.4599 mL	4.9198 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (275 KB) SDS (252 KB)

COA (251 KB)

Handling Instructions (2659 KB)

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

[2]. Preuss UW. Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.). Alcohol Clin Exp Res. 2012 Jun;36(6):967-9. doi: 10.1111/j.1530-0277.2012.01827.x. [Content Brief]

[3]. Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag. 2012;8:45-53. [Content Brief]

[4]. Gahr M, et al. Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy.Nervenarzt. 2012 Aug 15. [Content Brief]

[5]. Palucha-Poniewiera A, Pilc A. Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6. [Content Brief]

[6]. Hinton DJ, et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology. 2012 Jun;62(8):2480-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H2O	1 mM	4.9198 mL	24.5990 mL	49.1981 mL	122.9952 mL
H2O	5 mM	0.9840 mL	4.9198 mL	9.8396 mL	24.5990 mL
	10 mM	0.4920 mL	2.4599 mL	4.9198 mL	12.2995 mL
	15 mM	0.3280 mL	1.6399 mL	3.2799 mL	8.1997 mL
	20 mM	0.2460 mL	1.2300 mL	2.4599 mL	6.1498 mL
	25 mM	0.1968 mL	0.9840 mL	1.9679 mL	4.9198 mL
	30 mM	0.1640 mL	0.8200 mL	1.6399 mL	4.0998 mL
	40 mM	0.1230 mL	0.6150 mL	1.2300 mL	3.0749 mL
	50 mM	0.0984 mL	0.4920 mL	0.9840 mL	2.4599 mL
	60 mM	0.0820 mL	0.4100 mL	0.8200 mL	2.0499 mL
	80 mM	0.0615 mL	0.3075 mL	0.6150 mL	1.5374 mL
	100 mM	0.0492 mL	0.2460 mL	0.4920 mL	1.2300 mL